A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., alleging that the company made materially false and misleading statements regarding the potential of its drug setrusumab, as well as the risks associated with its Phase III Orbit and Cosmic studies in patients with Osteogenesis Imperfecta. The suit claims that Ultragenyx assured investors of setrusumab's ability to decrease fracture rates, despite knowing that increased bone density observed in studies did not correlate with reduced fractures. It is alleged that these statements led investors to purchase shares at inflated prices, resulting in damages when the true information emerged. Investors who bought Ultragenyx stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the litigation, with a deadline of April 6, 2026 to seek lead plaintiff status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ultragenyx Pharmaceutical Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202602132221NEWSFILECNPR____20260213_283848_1) on February 14, 2026, and is solely responsible for the information contained therein.